- French clinical-stage biotech Cellectis ( NASDAQ: CLLS ) on Monday said the U.S. Food and Drug Administration (FDA) had cleared its investigational new drug (IND) application for its CAR-T treatment UCART20x22 for non-Hodgkin lymphoma.
- The company can now start a phase 1/2a clinical trial in patients with relapsed or refractory non-Hodgkin lymphoma.
- CLLS said it plans to begin enrolling patients in the study in H2 this year.
- U.S.-listed shares of CLLS were 2.7% higher at $3.08 after hours.
For further details see:
FDA clears Cellectis' investigational new drug application for lymphoma treatment